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Abstract
Objective: The aim of this study was to evaluate the diagnostic potential of low-dose adenosine
stress echocardiography in detection of myocardial viability.
Background:  Vasodilation through low dose dipyridamole infusion may recruit contractile
reserve by increasing coronary flow or by increasing levels of endogenous adenosine.
Methods: Forty-three patients with resting dyssynergy, due to previous myocardial infarction,
underwent low-dose adenosine (80, 100, 110 mcg/kg/min in 3 minutes intervals) echocardiography
test. Gold standard for myocardial viability was improvement in systolic thickening of dyssinergic
segments of ≥ 1 grade at follow-up. Coronary angiography was done in 41 pts. Twenty-seven
patients were revascularized and 16 were medically treated. Echocardiographic follow up data (12
± 2 months) were available in 24 revascularized patients.
Results: Wall motion score index improved from rest 1.55 ± 0.30 to 1.33 ± 0.26 at low-dose
adenosine (p < 0.001). Of the 257 segments with baseline dyssynergy, adenosine echocardiography
identified 122 segments as positive for viability, and 135 as necrotic since no improvement of
systolic thickening was observed. Follow-up wall motion score index was 1.31 ± 0.30 (p < 0.001 vs.
rest). The sensitivity of adenosine echo test for identification of viable segments was 87%, while
specificity was 95%, and diagnostic accuracy 90%. Positive and negative predictive values were 97%
and 80%, respectively.
Conclusion: Low-dose adenosine stress echocardiography test has high diagnostic potential for
detection of myocardial viability in the group of patients with left ventricle dysfunction due to
previous myocardial infarction. Low dose adenosine stress echocardiography may be adequate
alternative to low-dose dobutamine test for evaluation of myocardial viability.
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Background
The detection of reversible myocardial dysfunction has
clinical and prognostic significance, as recent studies have
suggested that patients with nonrevascularized viable
myocardium are at increased risk to suffer later cardiac
events [1,2], and that dysfunctional but viable segments
may recover after revascularization [3,4]. In the past dec-
ade, promising results have been reported in identifying
physiological markers of myocardial viability with 201Tl
scintigraphy and PET imaging [5–9]. Echocardiography
using low and high doses of dobutamine [10,11] and
dipyridamole [12], or both [13], was also successfully
introduced as a cost-effective method with comparable
diagnostic potential available in everyday clinical practice.
The physiologic basis for using pharmacological agents in
identification of myocardial viability relies on the demon-
stration of residual contractile reserve in basally dysfunc-
tional segments. Such reserve can be elicited either by
direct stimulation of β1 adrenoreceptors with dob-
utamine, or through a flow mediated increase in contrac-
tile function linked to endogenous adenosine
accumulation achieved by intravenous infusion of dipyri-
damole [14,15]. The potential advantage of adenosine
over dipyridamole, in addition to the extremely short half
life (<10 sec) and rapid onset of action, relies on adenos-
ine direct action on A2 receptors, which increases blood
flow [16,17], and other possible mechanisms such as
replenishment of high energy phosphate stores, decrease
in myocardial oxygen consumption, and inhibition of
neutrophile action [18–20]. As shown for low dose dipy-
ridamole testing [12,13], lowest adenosine dose eliciting
viability, but not provoking ischemia, should be tested for
detection of myocardial viability by echocardiography.
Therefore, the aim of our study was to evaluate diagnostic
value of low dose adenosine stress echocardiography test
for identification of myocardial viability.
Methods
Study Population
Forty-three patients (34 men and 9 women, mean age 49
± 9) with history of previous myocardial infarction (more
than 3 months before low dose adenosine stress echocar-
diography test) and resting wall motion dyssynergy were
enrolled in the study. Inclusion criteria were: technically
satisfactory acoustic window, no history of high degree
atrioventricular block, sick sinus syndrome and severe
asthmatic or chronic obstructive pulmonary disease. All
patients had a previous Q-wave myocardial infarction.
Twenty-two patients (51%) were on antianginal therapy,
consisting of nitrates in 21 (49%), calcium antagonist in
9 (20%), and β-blockers in 9 (20%) patients. Theophyl-
line, caffeine-containing products and dipyridamole prep-
arations were not allowed for at least 12 h before the test.
The site of myocardial infarction was anteroseptal in 29,
inferior in 8, anterolateral in 3, inferolateral in 1, and lat-
eral in 2 patients.
Coronary angiography was performed in 41 patients. Sig-
nificant coronary artery disease (>50% diameter stenosis)
of one vessel was present in 30 patients, of two vessels in
9 patients and of three vessels in 2 patients. Coronary
revascularization was performed in 27 (63%) patients,
whereas 16 (37%) patients were medically treated. None
of the patients showed clinical, enzymatic, electrocardio-
graphic or echocardiographic evidence of myocardial inf-
arction during revascularization procedure or follow-up
period, and all were considered to have had successful
revascularization. Echocardiographic follow-up data were
available in 24 revascularized patients after 12 ± 2
months.
Low Dose Adenosine Stress Echocardiography Protocol
An infusion line was placed in the right anterocubital
vein. Adenosine was administered by incremental infu-
sion doses of 80, 100 and 110 µg/kg/min at 3 minutes
intervals (Figure 1). Blood pressure, heart rate and 12-lead
electrocardiogram were followed continuously during
adenosine infusion, and recorded at the end of each stage.
Patients were asked to describe the symptoms they
experienced.
Echocardiographic Monitoring and Analysis
Two-dimensional echocardiography was performed con-
tinuously before, during and after adenosine infusion,
using a commercially available imaging system (Toshiba
SSH60A; Diasonics) with the patient in the left lateral
decubitus position. After cessation of the test, echocardio-
graphic imaging was continued until hemodynamic vari-
ables or left ventricular wall motion returned to the basal
state. All standard echocardiographic views (apical two-,
four-, and five-chamber, and parasternal long-axis and
Figure 1
Low dose adenosine stress echocardiography study protocol
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short-axis views) were obtained. Echocardiographic
images were recorded on VHS videotape for subsequent
playback and analysis. An echocardiography test was
interpreted from the off-line digitalized videotapes
(Image View, ATL) with a side-by-side display of rest and
peak stress images in a cine-loop mode. Regional wall
motion was assessed according to the recommendations
of the American Society of Echocardiography, by a 16-seg-
ment model [21]. In all studies, segmental wall motion
was semi quantitatively graded as follows: normal = 1,
hypokinetic, marked reduction in endocardial motion =
2, akinetic, virtual absence of inward motion and thicken-
ing = 3, and dyskinetic, paradoxic wall motion away from
the center of left ventricle in systole = 4. A criterion for
possible myocardial viability was improvement in systolic
thickening of dyssynergic segments of ≥ 1 grade (hypoki-
netic segment becoming normal, or akinetic segment
becoming hypokinetic), at peak adenosine stress test. The
gold standard for viability was improvement in systolic
thickening of previously dyssynergic segments of ≥ 1 grade
at resting state at follow-up.
A wall motion score index was calculated for rest and peak
stress (9th minute of adenosine infusion) echocardio-
grams in all patients dividing the sum of individual seg-
ment scores by the number of interpreted segments.
Inadequately visualized segments were not scored.
Echocardiographic follow-up was obtained ≥ 3 months
after adenosine test and/or revascularization procedure.
Two experienced observers analyzed all studies separately.
Interobserver agreement was 94% for detection of viabil-
ity for adenosine testing, and 96% for identification of
viable segments at follow-up.
Statistical Analysis
Data are expressed as mean value ± SD. Differences in
hemodynamic values and wall motion score index before
and at peak adenosine infusion were tested for signifi-
cance with the Student t test. Dichotomous variables were
compared by chi-square (McNemar test for paired propor-
tions). Sensitivity, specificity and diagnostic accuracy were
calculated according to the standard definitions. A P value
<0.05 was considered statistically significant.
Results
Baseline Echocardiographic Findings
All patients had a regional dyssynergy in the resting
echocardiogram in the territory of previous myocardial
infarction. There were 257/688 segments with baseline
dyssynergy. The mean resting wall motion score index was
1.55 ± 0.30.
Clinical and Hemodynamic Data
None of the 43 patients had significant side effects. Seven
patients (16%) complained of flushing. One patient had
biphasic response (improvement of function followed by
subsequent deterioration) at dose of 110 mcg/kg/min,
with no signs of ischemia on electrocardiogram.
The systemic hemodynamic findings, blood pressure,
heart rate, in baseline conditions and during the pharma-
cological stress tests are shown in Figure 2 and 3. Systolic
blood pressure (rest: 133 ± 15 mmHg) decreased signifi-
cantly during the test (127 ± 18 mmHg, p < 0.001 vs. rest),
while heart rate (75 ± 12 bpm at rest) increased to 83 ± 20
bpm (p < 0.001).
Basal Echocardiography Findings
Thirty-one patients (72%) showed improved segmental
wall motion during low dose adenosine stress echocardi-
ography testing, whereas in 12 patients (28%) no contrac-
tile reserve could be identified. Wall motion score index
improved from resting 1.55 ± 0.30 to 1.35 ± 0.28 (p <
0.05) at low dose adenosine infusion.
Of the 257 segments with baseline dyssynergy low dose
adenosine echocardiography identified 122 segments as
viable, and 135 as "necrotic" according to absence of
improved thickening and contraction.
Figure 2
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The functional response was not influenced by beta-
blocker therapy.
Diagnostic Potential of Low Dose Adenosine Stress 
Echocardiography
Successful coronary revascularization was done in 27
patients; echocardiographic follow-up examination was
available in 24 (88%). Baseline echocardiography, before
low dose adenosine testing, showed in these 24 revascu-
larized patients a total of 122 dyssynergic segments.
Regional wall motion improved at follow-up by ≥ 1 grade
in 80 segments ("viable", 65%), whereas in the remaining
42 ("necrotic", 34%) no improvement could be observed.
Of the 80 viable segments, adenosine correctly identified
70 (sensitivity 87%). Of the 42 necrotic segments adeno-
sine correctly identified 40 (specificity 95%). The diagnos-
tic accuracy of adenosine stress echocardiography in
predicting the behavior of the basally dyssynergic myocar-
dial segments after revascularization was 90%. Positive
and negative predictive values were 97% and 80%, respec-
tively (Figure 4). Wall motion score index improved sig-
nificantly in revascularized patients during follow-up
period (1.54 ± 0.28 vs. 1.31 ± 0.30, p < 0.01).
Patients on beta-blocker therapy, who were responders
during adenosine echocardiography testing (6 out of 9)
showed functional improvement after revascularisation at
follow-up. In these 9 patients the WMSI was 1.55 ± 0.25
at baseline, 1.35 ± 0.27 at peak adenosine (p < 0.01), and
1.36 ± 0.34 (p < 0.01) at follow-up. In this subset, the
diagnostic accuracy of adenosine for predicting viability
was 88%.
Discussion
Results of our study have shown that low dose adenosine
stress echocardiography testing may identify potentially
reversible myocardial dysfunction with high diagnostic
confidence and feasibility.
It has been shown that revascularization of viable seg-
ments correlates with enhancement of regional and global
myocardial function [22]. This is in agreement with our
finding that wall motion score index indeed improved in
revascularized patients at follow-up.
Nevertheless, we observed also spontaneous recovery of
the segments in medically treated patients, but in less
extent than was predicted by adenosine echocardiogra-
phy, and wall motion score index at follow up in this
group of patients did not improve.
Infusion of low dose adenosine has shown superior
hemodynamic and safety profile.
Figure 3
Hemodynamic data during low dose adenosine stress 
echocardiography test.
0
20
40
60
80
100
REST ADO
75 83
*
p<0.001
bpm
Heart rate
Figure 4
Diagnostic value of low dose adenosine stress echocardiog-
raphy test in revascularized patients. Sn sensitivity, Sp specifi-
city, Acc diagnostic accuracy.
0
20
40
60
80
100
Sn Sp Acc ppv npv
`
87   95   90     97   80
%Cardiovascular Ultrasound 2003, 1 http://www.cardiovascularultrasound.com/content/1/1/7
Page 5 of 7
(page number not for citation purposes)
The possible physiologic basis for improvement in thick-
ening and contractility of dyssynergic myocardial seg-
ments during low dose adenosine infusion could be the
consequence of the following mechanisms:
1) Increase in blood flow within the ventricular wall that
leads to myofiber stretching and an increase in contractile
force through the Gregg phenomenon [23];
2) Functional improvement of dyssynergic segments dur-
ing increased coronary flow states that are related to ade-
nosine effect on microvasculature, recruitment of adjacent
capillary beds especially in the endocardium and
improved oxygen supply consumption ratios;
3) Cardioprotective effects of adenosine on glucose
metabolism that tends to decrease cellular acidosis and Ca
++ overload, which may be associated with beneficial
effects on mechanical function [24].
In addition, Rovai et al.[25] using dipyridamole contrast
echocardiography, have shown that myocardial perfusion
in the asynergic ventricular walls could be either preserved
at baseline or recruitable by vasodilation. The primary
effect of dipyridamole is adenosine A2-receptor mediated
vasodilation on the coronary arteriole smooth muscle
cell, leading to an increase in flow [20]. Our data are con-
sistent with experimental and clinical studies [12,13,15],
showing that even very low doses of adenosine can evoke
contractile response in asynergic but viable segments.
Relation to Previous Studies
To our knowledge, there are a limited number of studies
in regard to adenosine echocardiography in detection of
viable myocardium. Our study is the first one that used
incremental low doses of adenosine in order to obtain
maximal functional response and to avoid possible
ishemia, that could be provoked with high adenosine
doses. Our intention was to design protocol with mini-
mum side effects and maximum diagnostic potentials,
which could be safely used in everyday clinical practice, in
patients with bad ventricular performance and in ordinary
echocardiography lab. There are published data with
higher adenosine doses (140 up to 180 mcg/kg/min)
safely used in cath lab to assess the coronary flow reserve
using intracoronary Doppler flow-wire, but this data are
related mainly to the patients with myocardial infarction
but with good ventricles [26,27]. The fact that test is per-
formed in the cath lab diminishes the possibility of unde-
sirable serious adverse events.
This protocol may have advantage over dobutamine in the
patients with severe left ventricular dysfunction. Proar-
rhythmogenic effect of dobutamine is well known and it
has been reported that occurrence of tachyarrhythmias
during dobutamine stress testing are predicted by the
extent of the left ventricular dysfunction but not by the
presence or the extent of coronary artery disease [28].
One of the advantages of adenosine over dipyridamole
and dobutamine is its short time to peak action allowing
short duration of the test and its short half-life in circula-
tion so there is no need for antidote.
Kranidis and al. [29] reported moderate sensitivity, specif-
icity, positive and negative predictive value (54%, 86%,
65% and 80%, respectively), of adenosine stress echocar-
diography in detecting viable myocardium in 52 patients
with previous myocardial infarction. In their study they
have used only deterioration of segmental motion as a
sign of viability during infusion of 140 mcg/kg/min of
adenosine. This ischemia-based approach may miss the
detection of viable, albeit not ischemic segments.
Case et al. [30] also reported the ability of adenosine
echocardiography to detect viable myocardial segments in
patients following thrombolytic therapy. They compared
adenosine-induced changes in myocardial function in the
infarct related territory with thallium scintigraphy criteria
for viability. Out of 12 patients with evidence of viable
myocardium by thallium scintigraphy criteria, only three
patients demonstrated an improvement in regional func-
tion during adenosine infusion(140 µg/kg/min), and 9
had ischemic response. Actually, regional function deteri-
orated in patients with high grade (95 ± 2%) stenosis and
improved in those with nonflow limiting stenosis (66 ±
25%, p = 0.03). This is in keeping with observation of the
previous study [29], that ischemic dose of adenosine (140
µg/kg/min) would more likely provoke immediately
deterioration of function and ischemia, rather than bipha-
sic response – hallmark of viability, that could be seen
with our proposed low dose stepwise infusion of
adenosine.
Our data are comparable with results of Varga et al. [12]
using infra-low dose dipyridamole (0.28 mg/kg) stress
echocardiography for viability detection, reporting sensi-
tivity and specificity of 78% and 94%, respectively. They
compared these results with results achieved with low-
dose dobutamine stress echocardiography (up to 10 µg/
kg/min) in the same group of patients, yielding the sensi-
tivity of 76% and specificity of 94%, with a concordance
of the methods of 93%. Also, searching for the superior
study protocol, Picano et al [13] have suggested the com-
bined low dose dipyridamole – low dose dobutamine
stress echocardiography, reporting increase in sensitivity
from 67% (low dose dipyridamole) to 94% (combined
low dose dipyridamole-dobutamine), with a slight and
nonsignificant decrease in specificity (95% to 92%).Cardiovascular Ultrasound 2003, 1 http://www.cardiovascularultrasound.com/content/1/1/7
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Sicari et al. [31] also used low dipyridamole echocardiog-
raphy to assess the prognostic significance of myocardial
viability in patient with severe left ventricular ischemic
dysfunction. For the viability presence they have used cut-
off value of delta wall motion score index = 0.20 that cor-
responds on average to four segments showing viability,
which is equivalent to 25% of the ventricle. The presence
of myocardial viability at low dipyridamole echo test was
the only independent predictor exerting protective effect
on survival in revascularized patients.
Study limitations
The results we obtained with a new proposed protocol
should be confirmed in the large scale multicenter study.
As the test result was not taken into account for decision
making for revascularization, our study reflects the real
life clinical routine. That explains why not every patient
positive for viability underwent revascularization
procedure.
The study population included patients with mild to
moderate reduction of left ventricular performance; aver-
age wall motion score index was 1.55 ± 0.30. Our new
protocol with incremental subischemic doses of
adenosine is designed for "bad" ventricles, but in our clin-
ical opinion it should be tested first for safety reasons and
ability to provoke functional response in patients with
less severe reduction of ventricular function. Nevertheless,
this protocol may have advantage by avoiding provoca-
tion of ischemia that could be seen with higher adenosine
doses, and rhythm disturbances that could be seen with
dobutamine infusion.
In our study there are no comparative data with dipyrida-
mole and dobutamine.
According to our results accuracy of adenosine testing is
not influenced by beta-blocker therapy and this could be
recommendation for its use in everyday clinical practice
when it is not possible to rule out therapy for safety
reasons.
The echocardiographically documented improvement of
wall motion at follow-up was used as the definite method
for evaluating the accuracy of stress-induced functional
improvement, that may, per se, represent methodological
limitation, since independent standards (fluorodeoxyglu-
cose by positron emission tomography or thallium uptake
by scintigraphy) were not utilized. The interpretation of
digitally acquired echocardiography images was subjec-
tive and semiquantitive. However, in our study two inde-
pendent observers reviewed all the studies, with low
interobserver variability. When disagreement occurred
regarding presence of viable segments, a third observer
reviewed the study and his judgment was accepted.
Clinical Implications
In the present study we have shown that low dose adeno-
sine stress echocardiography test has high diagnostic
potential and feasibility in the group of patients with mild
to moderate left ventricular impairment. Good effective-
ness should justify higher adenosine price compared to
dobutamine and dipyridamole. The study protocol and
efficacy of low dose adenosine stress echocardiography
should be assessed in larger number of patients with
severe left ventricular dysfunction in whom the clinical
question regarding the extent of viable tissue is most
important.
The presence of myocardial viability can guide the clinical
cardiologist towards more appropriate treatment by add-
ing more information to conventional ones such as ejec-
tion fraction, coronary anatomy and inducible ischemia
Low dose adenosine stress echocardiography test, with
excellent hemodynamic and safety profile, may be good
alternative to low dose dobutamine and dipyridamole
stress echocardiography testing for evaluation of myocar-
dial viability.
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